Provectus Pharmaceuticals Completes Patient Accrual in Phase 2C Clinical Trial of PH-10 for Psoriasis
Provectus Pharmaceuticals Completes Patient Accrual in Phase 2C Clinical Trial of PH-10 for Psoriasis
KNOXVILLE, Tenn.–(BUSINESS WIRE)–Provectus Pharmaceuticals has completed patient accrual in its Phase 2C clinical trial of PH-10 for psoriasis.
Read more on Business Wire
Categories: Breast Cancer Information Tags: Accrual, Clinical, Completes, patient, PH10, Pharmaceuticals, Phase, Provectus, Psoriasis, Trial
Provectus completes enrollment in first cohort of PV-10 Phase 1 trial for liver cancer
Provectus completes enrollment in first cohort of PV-10 Phase 1 trial for liver cancer
Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announced today that it has completed enrollment in the first of two dose cohorts in its Phase 1 clinical trial of PV-10 for liver cancer, and that the therapy was very well tolerated by all three subjects treated, with substantial evidence of efficacy.
Read more on News-Medical-Net
Categories: Breast Cancer In Men Tags: cancer, cohort, Completes, enrollment, first, liver, Phase, Provectus, PV10, Trial
Provectus Pharmaceuticals to Use Numoda’s TruPoints System to Facilitate Transactions with Potential Licensing …
Provectus Pharmaceuticals to Use Numoda’s TruPoints System to Facilitate Transactions with Potential Licensing …
KNOXVILLE, Tenn.—-Provectus Pharmaceuticals, Inc. , a development-stage oncology and dermatology biopharmaceutical company, has signed an agreement with Numoda Capital Innovations LLC to license its TruPoints® strategic partnering platform.
Read more on Business Wire via Yahoo! Finance
Categories: Metastatic Breast Cancer Tags: Facilitate, Licensing, Numoda's, Pharmaceuticals, Potential, Provectus, system, Transactions, TruPoints